Yüklüyor......
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
Despite the introduction of immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and, more recently, monoclonal antibodies (mAbs), in the chemotherapy regimens for newly diagnosed (NDMM) and relapsed/refractory MM (RRMM), the occurrence of drug resistance remains a challenge in MM patients....
Kaydedildi:
| Yayımlandı: | Drug Des Devel Ther |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8180291/ https://ncbi.nlm.nih.gov/pubmed/34103900 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S267404 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|